Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senores PharmaceuticalsNSE:SENORES -0.42%18 3-Year ROIIC % is 10.77 as of Mar. 2026, which is 12% above its 10-year median of 9.62. GuruFocus rates NSE:SENORES with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 946 Drug Manufacturers companies, Senores Pharmaceuticals ranks better than 60.57% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Senores Pharmaceuticals's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 10.77%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Senores Pharmaceuticals's 3-Year ROIIC % or its related term are showing as below:
NSE:SENORES's 3-Year ROIIC % is ranked better than 60.57% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs NSE:SENORES: 10.77
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Senores Pharmaceuticals 3-Year ROIIC % Related Terms
Senores Pharmaceuticals 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SENORES vs LLY, JNJ, ABBV: 3-Year ROIIC % Comparison
For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senores Pharmaceuticals 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Senores Pharmaceuticals's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Senores Pharmaceuticals (NSE:SENORES) has a 3-Year ROIIC % of 10.77 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Senores Pharmaceuticals and its competitors. This is 12% above median its historical median of 9.62. Over the past decade, Senores Pharmaceuticals' 3-Year ROIIC % has ranged from 8.46 to 10.77. According to the industry distribution chart, Senores Pharmaceuticals ranks #373 out of 946 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Senores Pharmaceuticals' 3-Year ROIIC % too high?
Senores Pharmaceuticals' current 3-Year ROIIC % of 10.77 is 12% above median its 10-year median of 9.62. Over the past 10 years, this metric has ranged from a low of 8.46 to a high of 10.77. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Senores Pharmaceuticals' value of 10.77 is 189.5% above this industry median. Based on the distribution chart, Senores Pharmaceuticals ranks #373 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' 3-Year ROIIC % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Senores Pharmaceuticals ranks #373 out of 946 companies for 3-Year ROIIC %. This puts Senores Pharmaceuticals in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Senores Pharmaceuticals' value of 10.77 is 189.5% above this benchmark. Historically, Senores Pharmaceuticals' own 3-Year ROIIC % has ranged from 8.46 to 10.77 over the past decade. While the company's 10-year median is 9.62 vs. the industry median of 3.72, Senores Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senores Pharmaceuticals's current 3-Year ROIIC % of 10.77 is 189.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Senores Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senores Pharmaceuticals's current 3-Year ROIIC % is 10.77, which is 12% above median its own 10-year median of 9.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current 3-Year ROIIC % of 10.77. The current 3-Year ROIIC % is 10.77, which is 12% above median its 10-year median of 9.62 and 189.5% above the Drug Manufacturers industry median of 3.72. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current 3-Year ROIIC % is 10.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score
Get the complete analysis for NSE:SENORES
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SENORES has been successfully added to your 
